Merck Seeks To Toss Doctor's Fosamax Testimony

Law360, New York (August 19, 2009, 5:02 PM EDT) -- Pharmaceutical giant Merck & Co. Inc. has asked a judge to exclude the testimony of the doctor who said his patient, the plaintiff in a bellwether case alleging harmful drug side effects, developed a degenerative bone disease from the osteoporosis drug Fosamax.

In a motion filed Tuesday in the U.S. District Court for the Southern District of New York, Merck contends that testimony from Dr. Patrick Anastasio lacks relevancy and “does nothing to advance” plaintiff Shirley Boles' theory that she developed “stage 0” osteonecrosis of the...
To view the full article, register now.